{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:22:43Z","timestamp":1759962163501,"version":"3.32.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":2095,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.14283\/jpad.2018.42","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T07:10:22Z","timestamp":1614323422000},"page":"20-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?"],"prefix":"10.1016","volume":"6","author":[{"given":"Donna A.","family":"Messner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rabins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"Downing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Irizarry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.L.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Al Naber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Dabbous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Fillit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gabler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Krakauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Payzant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tyrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Van Amerongen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wuest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.14283\/jpad.2018.42_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer's disease drug\u2013development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimer's Research & Therapy."},{"issue":"4","key":"10.14283\/jpad.2018.42_bib2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"The Lancet Neurology"},{"issue":"12","key":"10.14283\/jpad.2018.42_bib3","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","article-title":"Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case\u2013control study","volume":"11","author":"Reiman","year":"2012","journal-title":"The Lancet Neurology"},{"issue":"5","key":"10.14283\/jpad.2018.42_bib4","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease","volume":"132","author":"Jack","year":"2009","journal-title":"Brain"},{"issue":"9","key":"10.14283\/jpad.2018.42_bib5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease","volume":"367","author":"Bateman","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.14283\/jpad.2018.42_bib6","first-page":"353","article-title":"Alzheimer's Disease in Down Syndrome","volume":"1","author":"Head","year":"2012","journal-title":"Eur J Neurodegener Dis"},{"issue":"3","key":"10.14283\/jpad.2018.42_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.mcna.2013.01.001","article-title":"International Work Group Criteria for the Diagnosis of Alzheimer Disease","volume":"97","author":"Cummings","year":"2013","journal-title":"Medical Clinics of North America"},{"issue":"4","key":"10.14283\/jpad.2018.42_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMe1714638","article-title":"Amyloid\u2013Beta Solubility in the Treatment of Alzheimer's Disease","volume":"378","author":"Murphy","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.14283\/jpad.2018.42_bib9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.neubiorev.2016.12.020","article-title":"Neurophysiological assessment of neural network plasticity and connectivity: Progress towards early functional biomarkers for disease interception therapies in Alzheimer's disease","volume":"73","author":"Walsh","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"author":"US Food and Drug Administration","key":"10.14283\/jpad.2018.42_bib10"},{"year":"2017","author":"Jack","journal-title":"2018 NIA\u2013AA Research Framework to Investigate the Alzheiemr's Disease Continuum (DRAFT)","key":"10.14283\/jpad.2018.42_bib11"},{"issue":"4","key":"10.14283\/jpad.2018.42_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jalz.2017.02.001","article-title":"2017 Alzheimer's disease facts and figures","volume":"13","author":"Alzheimer's Association","year":"2017","journal-title":"Alzheimer's & Dementia"},{"issue":"3","key":"10.14283\/jpad.2018.42_bib13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/jgs.12132","article-title":"Health\u2013Related Resource Use and Costs in Elderly Adults with and without Mild Cognitive Impairment","volume":"61","author":"Zhu","year":"2013","journal-title":"Journal of the American Geriatrics Society"},{"issue":"8","key":"10.14283\/jpad.2018.42_bib14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jalz.2015.01.007","article-title":"Direct medical costs and source of cost differences across the spectrum of cognitive decline: A populationbased study","volume":"11","author":"Leibson","year":"2015","journal-title":"Alzheimer's & Dementia."},{"issue":"8","key":"10.14283\/jpad.2018.42_bib15","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/jgs.14227","article-title":"Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis","volume":"64","author":"Lin","year":"2016","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.14283\/jpad.2018.42_bib16","first-page":"S191","article-title":"ADCS Prevention Instrument Project: pharmacoeconomics: assessing health\u2013related resource use among healthy elderly","author":"Sano","year":"2006","journal-title":"Alzheimer Disease & Associated Disorders"},{"issue":"2","key":"10.14283\/jpad.2018.42_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/gps.1858","article-title":"Point and 5\u2013year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study","volume":"23","author":"Steinberg","year":"2008","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"5","key":"10.14283\/jpad.2018.42_bib18","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1176\/appi.ajp.2014.13060821","article-title":"Baseline Neuropsychiatric Symptoms and the Risk of Incident Mild Cognitive Impairment: A Population\u2013Based Study","volume":"171","author":"Geda","year":"2014","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.14283\/jpad.2018.42_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0809578","article-title":"Disclosure of APOE Genotype for Risk of Alzheimer's Disease","volume":"361","author":"Green","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.14283\/jpad.2018.42_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/14636778.2011.552300","article-title":"Informed choice in direct\u2013to\u2013consumer genetic testing for Alzheimer and other diseases: lessons from two cases","volume":"30","author":"Messner","year":"2011","journal-title":"New Genetics and Society"},{"year":"2009","author":"Nuffield Council on Bioethics","journal-title":"Dementia: Ethical Issues. London: Nuffield Council on Bioethics","key":"10.14283\/jpad.2018.42_bib21"},{"key":"10.14283\/jpad.2018.42_bib22","article-title":"Study partners perform essential tasks in dementia research and can experience burdens and benefits in this role","author":"Black","year":"2016","journal-title":"Dementia. May"},{"author":"Progress and Challenges in Alzheimer's Disease Drug Development","key":"10.14283\/jpad.2018.42_bib23"},{"issue":"4","key":"10.14283\/jpad.2018.42_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jalz.2014.01.007","article-title":"Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease","volume":"11","author":"Bradley","year":"2015","journal-title":"Alzheimer's & Dementia."},{"year":"2012","author":"Pearson","journal-title":"Diagnostic Tests for Alzheimer' s Disease: Generating and Evaluating Evidence to Inform Insurance Coverage Policy","key":"10.14283\/jpad.2018.42_bib25"},{"year":"2016","author":"Holtzman","journal-title":"Alzheimer's Disease\u2013Related Dementias Summit: Report to the National Advisory Neurological Disorders and Stroke Council","key":"10.14283\/jpad.2018.42_bib26"},{"author":"Agency for Healthcare Research and Quality","key":"10.14283\/jpad.2018.42_bib27"},{"year":"2017","author":"P. Aisen","journal-title":"EU\/US\/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials","key":"10.14283\/jpad.2018.42_bib28"},{"year":"2017","author":"Webster","journal-title":"Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations","key":"10.14283\/jpad.2018.42_bib30"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724004965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724004965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:51:54Z","timestamp":1736470314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724004965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2274580724004965"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2018.42","relation":{},"ISSN":["2274-5807"],"issn-type":[{"type":"print","value":"2274-5807"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2018.42","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}